Alantra Private Equity has added two dental laboratories to its AIVORIQ platform, pushing the group past 20 sites across Spain. The move follows a mix of double‑digit organic growth and targeted buy‑and‑build deals. Owners of the new labs have already reinvested in the platform, signaling confidence in the strategy today.

AIVORIQ currently generates close to €40 million in annual revenue and aims to reach around 30 laboratories nationwide. The latest acquisitions reinforce its core model of scaling through complementary add‑ons while preserving local ownership. Management plans to test international expansion into the UK, Germany and Italy once the domestic network stabilizes.

For investors, the deal expands Alantra’s foothold in a high‑margin specialty market and positions AIVORIQ for further consolidation. With a proven growth engine and a clear target of 30 labs, the platform is set to generate stronger cash flows and attract future buyers or an IPO. The transaction underscores the sector’s appeal to private‑equity buyers seeking steady, reinvestable earnings significantly.